Norge - norsk - Statens legemiddelverk

theramex ireland limited - risedronatnatrium - tablett, filmdrasjert - 35 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - kalsiumhomeostase - behandling av osteoporose hos postmenopausale kvinner med økt risiko for brudd.

Den europeiske union - norsk - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - osteoporose - kalsiumhomeostase - livogiva is indicated in adults. behandling av osteoporose hos postmenopausale kvinner og hos menn med økt risiko for brudd. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. behandling av osteoporose assosiert med vedvarende systemisk glukokortikoid terapi hos kvinner og menn med økt risiko for brudd.

Den europeiske union - norsk - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - leiomyomer - hypofysiske og hypotalamiske hormoner og analoger - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Den europeiske union - norsk - EMA (European Medicines Agency)

theramex ireland limited - follitropin alfa - anovulasjon - sex hormoner og modulatorer av genital systemet, - i voksen womenanovulation (inkludert polycystisk ovarie syndrom) hos kvinner som har vært responderer på behandling med clomifene citrate;stimulering av multifollicular utvikling hos kvinner som gjennomgår superovulation for assistert reproduktive teknologier (kunst), for eksempel in vitro-fertilisering (ivf), gamete intra-fallopian transfer zygote og intra-fallopian transfer;ovaleap i forbindelse med en luteinising hormon (lh) preparatet er anbefalt for stimulering av follikulær utvikling hos kvinner med alvorlig lh og fsh-mangel. i kliniske forsøk for disse pasientene ble definert av en endogen serum lh-level < 1. 2 iu/l. i voksen menovaleap er indikert for stimulering av spermatogenese i menn som har medfødt eller ervervet hypogonadotropic hypogonadisme med samtidig bruk av humant choriongonadotropin (hcg) terapi.

Den europeiske union - norsk - EMA (European Medicines Agency)

theramex ireland limited - nomegestrol acetat, estradiol - prevensjon - sex hormoner og modulatorer av genital systemet, - oral contraception,.

Norge - norsk - Statens legemiddelverk

orifarm as - risedronatnatrium - tablett, filmdrasjert - 35 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

endoceutics s.a. - prasterone - postmenopause menopause~~pos=headcomp - andre kjønnshormoner og modulatorer av genital systemet - intrarosa er indisert for behandling av vulvar og vaginal atrofi hos postmenopausale kvinner som har moderate til alvorlige symptomer.

Norge - norsk - Statens legemiddelverk

2care4 aps - prasteron - vagitorie - 6.5 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft-avvisning - immunsuppressive - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.